A Phase 1/2 Study of AB-2100 Cellular Therapy in People With Advanced Clear Cell Renal Cell Carcinoma

Share

Full Title

An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy Of AB-2100 in Patients with Recurrent Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CCRCC)

Purpose

The purpose of this study is to find the best dose of AB-2100 cellular therapy for people with clear cell renal cell cancer (CCRCC). The people in this study have CCRCC that came back or spread after treatment.

AB-2100 is a type of immunotherapy made from your own white blood cells called T cells. If you join this study, we will collect some of your T cells. We will then add a gene that will help your T cells find and kill your cancer cells. These genetically changed T cells are called integrated circuit T (ICT) cells. Treatments made from them are called ICT therapies. AB-2100 and the other medications used in this study are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have CCRCC that came back or spread after treatment.
  • Have completed prior anti-cancer treatments at least 2 weeks before getting the study therapy.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Ritesh Kotecha’s office at 646-422-4839.

Protocol

24-197

Phase

Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators

ClinicalTrials.gov ID

NCT06245915